Daniel P Bondeson
Systematic profiling of conditional degron tag technologies for target validation studies
Daniel P. Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, Thomas A. Skipper, Thomas C. Atack, Nolan Bick, Meilani Ching, Andrew A. Guirguis, Jason Kwon, Carly Langan, Dylan Millson, Brenton R. Paolella, Kevin Tran, Sarah J. Wie, Francisca Vazquez, Zuzana Tothova, Todd R. Golub, William R. Sellers, Alessandra Ianari
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer
Daniel P. Bondeson, Brenton R. Paolella, Adhana Asfaw, Michael V. Rothberg, Thomas A. Skipper, Carly Langan, Gabriel Mesa, Alfredo Gonzalez, Lauren E. Surface, Kentaro Ito, Mariya Kazachkova, William N. Colgan, Allison Warren, Joshua M. Dempster, John M. Krill-Burger, Maria Ericsson, Andrew A. Tang, Iris Fung, Emily S. Chambers, Mai Abdusamad, Nancy Dumont, John G. Doench, Federica Piccioni, David E. Root, Jesse Boehm, William C. Hahn, Michael Mannstadt, James M. McFarland, Francisca Vazquez, Todd R. Golub
Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
George M. Burslem, Daniel P. Bondeson, Craig M. Crews
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
George M. Burslem, Anna Reister Schultz, Daniel P. Bondeson, Christopher A. Eide, Samantha L. Savage Stevens, Brian J. Druker, and Craig M. Crews
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson, Blake E. Smith, George M. Burslem, Alexandru D. Buhimschi, John Hines, Saul Jaime-Figueroa, Jing Waang, Brian D. Hamman, Alexey Ishchenko, Craig M. Crews
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem, Blake E. Smith, Ashton C. Lai, Saul Jaime-Figueroa, Daniel C. McQuaid, Daniel P. Bondeson, Momar Toure, Hanqing Dong, Yimin Qian, Jing Wang, Andrew P. Crew, John Hines, Craig M. Crews